Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Ionis Pharmaceuticals ( (IONS) ).
On January 7, 2026, Ionis Pharmaceuticals reported that its partner GSK delivered positive topline data from the pivotal Phase 3 B-Well 1 and B-Well 2 trials of bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, in more than 1,800 patients across 29 countries. The studies met their primary endpoint, showing statistically significant and clinically meaningful functional cure rates – defined as sustained hepatitis B surface antigen loss and undetectable viral DNA after a finite treatment course – with bepirovirsen plus standard of care outperforming standard therapy alone while maintaining an acceptable safety and tolerability profile. Given chronic hepatitis B’s global burden, low cure rates with current lifelong nucleos(t)ide analogue regimens and bepirovirsen’s recognition by regulators in the US, China and Japan, the Phase 3 success strengthens Ionis’s position in RNA-based antivirals, sets the stage for global regulatory submissions starting in the first quarter of 2026, and creates potential future revenue streams through up to $150 million in additional milestones and tiered royalties of 10–12% on any net sales from its 2019 licensing and collaboration agreement with GSK.
The most recent analyst rating on (IONS) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.
Spark’s Take on IONS Stock
According to Spark, TipRanks’ AI Analyst, IONS is a Neutral.
Ionis Pharmaceuticals’ overall stock score is driven by strong technical momentum and positive corporate events, which are offset by financial performance challenges and valuation concerns. The company’s strategic advancements and successful product launches provide a positive outlook, but profitability and cash flow issues remain significant risks.
To see Spark’s full report on IONS stock, click here.
More about Ionis Pharmaceuticals
Ionis Pharmaceuticals, based in Carlsbad, California, is a pioneer in RNA-targeted therapeutics with marketed medicines and a leading pipeline in neurology, cardiometabolic and other high-need disease areas. The company focuses on antisense oligonucleotide technologies and related genetic medicine approaches, aiming to develop transformative treatments for serious conditions in collaboration with large pharma partners such as GSK.
Average Trading Volume: 2,328,510
Technical Sentiment Signal: Buy
Current Market Cap: $12.72B
Learn more about IONS stock on TipRanks’ Stock Analysis page.